|本期目录/Table of Contents|

[1]李莎莎,陈 艳,曲建慧,等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床效果评价[J].传染病信息,2019,02:119-121138.
 LI Sha-sha,CHEN Yan,QU Jian-hui,et al.Clinical effect evaluation of entecavir combined with compound biejia ruangan tablet on chronic hepatitis B hepatic fibrosis[J].Infectious Disease Information,2019,02:119-121138.
点击复制

恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床效果评价(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年02期
页码:
119-121138
栏目:
论 著
出版日期:
2019-05-15

文章信息/Info

Title:
Clinical effect evaluation of entecavir combined with compound biejia ruangan tablet on chronic hepatitis B hepatic fibrosis
文章编号:
1007-8134(2019)02-0119-04
作者:
李莎莎陈 艳曲建慧谭 林王金玲孙艳玲杨永平
236015,阜阳市第二人民医院肝脏病科(李莎莎、谭林、王金玲);100039 北京,中国人民解放军总医院第五医学中心肝脏肿瘤诊疗与研究中心(陈艳、曲建慧、杨永平),病理科(孙艳玲)
Author(s):
LI Sha-sha CHEN Yan QU Jian-hui TAN Lin WANG Jin-ling SUN Yan-ling YANG Yong-ping*
Department of Hepatology, Fuyang No. 2 People’s Hospital, 236015, China
关键词:
乙型肝炎肝纤维化恩替卡韦复方鳖甲软肝片
Keywords:
hepatitis B hepatic fibrosis entecavir compound biejia ruangan tablet
分类号:
R512.62;R575.2
DOI:
10.3969/j.issn.1007-8134.2019.02.005
文献标识码:
A
摘要:
目的 探讨恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床疗效。方法 选取2014 年4 月— 2016 年3 月于我院治疗的64 例慢性乙型肝炎肝纤维化患者作为研究对象,按照随机、双盲、安慰剂对照原则将其分为对照 组(恩替卡韦联合安慰剂治疗)和治疗组(恩替卡韦联合复方鳖甲软肝片治疗),例数分别为37 例和27 例。治疗期间定 期进行血常规、血生化、HBV DNA、肝脏硬度(liver stiffness measurement, LSM)的检查,并观察2 组患者治疗前和治疗 72 周时肝穿刺活检的疗效。结果 入组64 例患者,其中59 例完成临床疗效观察。与治疗前相比,治疗后2 组患者ALT、 AST、TBIL、HBV DNA 水平及LSM 和肝纤维化评分均较治疗前明显下降(P 均< 0.05);在改善肝纤维化程度方面,治 疗组有效率为66.7%,明显高于对照组的45.8%,差异有统计学意义(P < 0.05)。结论 恩替卡韦联合复方鳖甲软肝片治 疗可改善慢性乙型肝炎肝纤维化患者的肝脏炎症和纤维化程度。
Abstract:
Objective To explore the clinical efficacy of entecavir with compound biejia ruangan tablet in the treatment of chronic hepatitis B hepatic fibrosis. Methods Sixty-four patients with chronic hepatitis B hepatic fibrosis were included in this study, who were treated in our hospital from April 2014 to March 2016. According to the principle of randomization, double blindness and placebo control, the involved patients were divided into control group (entecavir combined with placebo) and treatment group (entecavir combined with compound biejia ruangan tablet), with 37 cases and 27 cases, respectively. Blood routine, blood biochemistry, HBV DNA and liver stiffness measurement (LSM) were examined regularly during the treatment. The efficacy of liver biopsy before treatment and 72 weeks after treatment was observed in both groups. Results Among the 64 patients enrolled in the study, 59 cases of whom were completed in clinical observation. Compared with those pre-treatment, the levels of ALT, AST, TBIL, HBV DNA, LSM and liver fibrosis scores in the 2 groups after treatment were significantly decreased (P < 0.05). As for the improving degree of hepatic fibrosis, the effective rate of the treatment group was 66.7%, which was significantly higher than 45.8% in the control group (P < 0.05). Conclusions Entecavir combined with compound biejia ruangan tablet can improve the degree of liver inflammation and hepatic fibrosis in patients with chronic hepatitis B hepatic fibrosis.

参考文献/References


[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性 乙型肝炎防治指南(2010 年版)[J]. 中华肝脏病杂志, 2011,19(1):13-24.
[2] Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol, 2011, 25(2):195-202.
[3] Friedman SL. A deer in the headlights: BAMBI meets liver fibrosis [J]. Nat Med, 2007, 13(11):1281-1282.
[4] Friedman SL. Hepatic fibrosis-overview[J]. Toxicology, 2008, 254(3):120-129.
[5] DeMinicis S, Seki E, Oesterreicher C, et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells[J]. Hepatology, 2008, 48(6):2016-2026.
[6] Organization WH. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [EB/OL]. http://www. who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
[7] 何肖敏,黄坚. 肝纤维化血清学标志物研究新进展[J]. 中 华肝脏病杂志,2015,23(11):874-877.
[8] 曹建彪,陈永平,成军,等. 瞬时弹性成像技术(TE)临床 应用专家共识(2015 年)[J]. 中国肝脏病杂志(电子版), 2015,7(2):12-18.
[9] Chen YP, Liang XE, Zhang Q, et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J]. J Gastroenterol Hepatol, 2012, 27(7):1219-1226.
[10] 杨元素,李丽,黄夏寒. 恩替卡韦治疗慢性乙型肝炎的临床 研究[J]. 传染病信息,2017,30(1):34-37.
[11] Jiyao Wang. Clinical utility of entecavir for chronic hepatitis B in Chinese patients[J]. Drug Des Devel Ther, 2014, 8:13-24.
[12] 张健,任姣姣,李冰,等. 恩替卡韦治疗慢性乙型肝炎及乙 型肝炎肝硬化患者的疗效分析[J]. 传染病信息,2013, 26(3):158-160.
[13] 陈菊梅,杨永平,陈德永,等. 复方鳖甲软肝片治疗慢性乙 型肝炎肝纤维化的临床研究[J]. 中华实验和临床病毒学杂志, 2007,21(4):358-360.
[14] 张瑞凤,姚云洁,游忠岚,等. 复方鳖甲软肝片联合恩替卡 韦治疗慢性乙型肝炎肝纤维化的观察[J]. 第三军医大学学报, 2014,36(18):1961-1963.
[15] 姚云洁,杨才兴,巫继. 恩替卡韦联合复方鳖甲软肝片治疗 慢性乙型肝炎患者疗效观察[J]. 实用肝脏病杂志,2015, 18(4):356-359.
[16] 吴刚,何鸿雁,李烨,等. 复方鳖甲软肝片联合恩替卡韦对 HBV 相关肝硬化患者的临床疗效观察[J]. 中华肝脏病杂志, 2014,22(8):604-608.
[17] 杨年欢,袁国盛,周宇辰,等. 恩替卡韦联合复方鳖甲软肝 片治疗慢性乙型肝炎肝纤维化96 周的临床疗效[J]. 南方医 科大学学报,2016,36(6):775-779.

备注/Memo

备注/Memo:
[ 基金项目] “十二五”国家科技重大专项(2013ZX10005002-001)
[ 通信作者] 杨永平,E-mai: yongpingyang@hotmail.com
*Corresponding author, E-mail: yongpingyang@hotmail.com
更新日期/Last Update: 2019-05-15